ICHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ichor Holdings Ltd (ICHR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has positive analyst sentiment and potential growth catalysts, the recent sharp price decline (-11.16% in regular trading) and weak financial performance in the latest quarter suggest caution. Additionally, no significant trading signals or recent news catalysts are present to support an immediate buy decision.
The stock's technical indicators are mixed. The MACD is negative and expanding downward, suggesting bearish momentum. RSI is neutral at 42.727, indicating no clear overbought or oversold condition. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below key pivot support levels (S1: 42.662, S2: 39.9), which could indicate further downside risk.
Analysts have recently upgraded the stock with increased price targets, citing improving cyclical conditions and growth potential.
The company has guided for revenue growth in 2026, supported by strengthening demand in its end markets.
Recent sharp price decline (-11.16%) in regular trading, which could indicate negative sentiment or overreaction to market conditions.
Weak financial performance in Q4 2025, with declining revenue (-4.15% YoY) and negative net income, despite some improvement in EPS.
In Q4 2025, revenue dropped by 4.15% YoY to $223.6M, gross margin declined to 10.06% (-3.55% YoY), and net income remained negative at -$15.96M despite a 304.79% YoY improvement. EPS improved to -0.46 (+283.33% YoY), but overall financials indicate the company is still in recovery mode.
Analyst sentiment is positive, with multiple upgrades and price target increases in recent months. Stifel, DA Davidson, and B. Riley have all raised their price targets significantly, citing improving cyclical conditions, growth potential, and strong guidance for 2026. However, Oppenheimer downgraded the stock earlier in the year, citing valuation concerns and execution risks under the new CEO.
